Active Ingredient(s):Albiglutide FDA Approved: * April 15, 2014 Pharm Company: *GLAXOSMITHKLINE LLC Category:Diabetes
Albiglutide (trade names Eperzan in Europe and Tanzeum in the US) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes.
As of 2017 it is unclear if it affects a person's risk of death. GSK has announced that it intends to withdraw the drug from the worldwide market by July 2018 for economic reasons.
1 Medical uses
3 Side effects
* May have multiple approval dates, manufacturers, or labelers. 6 Discussions
Tanzeum 30 mg/.5ml Subcutaneous Injection, Powder, Lyophilized, for Solution